Journal: Advanced Science
Article Title: GPR37 Activation Alleviates Bone Cancer Pain via the Inhibition of Osteoclastogenesis and Neuronal Hyperexcitability
doi: 10.1002/advs.202417367
Figure Lengend Snippet: NPD1 is negatively correlated with cancer pain and CTX‐I level in patients with metastatic cancer. A) Schematic diagram for the design of the clinical study. B) Comparison of pain intensity via number rating score (NRS) in cancer patients with bone metastasis. These patients were divided into NPD1‐low and NPD1‐high groups according to their levels of serum NPD1. n = 40 patients in NPD1‐low group and n = 39 patients in NPD1‐high group. C) Correlation between serum NPD1 level and NRS score in the enrolled patients. n = 79 patients. D) Elisa measurement of plasma CTX‐I level in NPD1‐low (n = 40) and NPD1‐high (n = 39) patients. E) Correlation between plasma NPD1 level and plasma CTX‐I level in the enrolled patients (n = 79). F) Graphical abstract of the current study. GPR37 activation reduces cancer pain and cancer induced bone destruction via peripheral and neuronal mechanism. NPD1 or ARU acting on GPR37 expressed in macrophage could promote the release of IL‐10 via recruitment of β‐arrestin 2 which further inhibit cancer induced ostoclastogenesis. Moreover, GPR37 activation in DRG could suppress No. of action potentials via β‐arrestin 2 pathway, while GPR37 activation in SDH decreases the frequency of sEPSCs, both leading to the inhibition of cancer induced neuronal hyperexcitability. Data in A and C are expressed as median (interquartile range), and analyzed with Mann‐Whitney test (B, D) and Person correlation test (C, E), * p < 0.05.
Article Snippet: Elisa kits including NPD1 (Biomatik, EKF58060), CTX‐I (CUSABIO, CSB‐E11224 h), IL‐10 (CUSABIO, CSB‐E04594 m) were obtained and applied.
Techniques: Comparison, Enzyme-linked Immunosorbent Assay, Clinical Proteomics, Activation Assay, Inhibition, MANN-WHITNEY
Biomatik manufactures this product 
